Heron Therapeutics, Inc.

Heron Therapeutics Our mission is to improve the lives of patients by developing novel, best-in-class treatments to address some of the most important unmet patient needs. We aim to develop patient-focused solutions by applying our innovative science and technologies with well-known pharmacology.SUSTOL® (granisetron) extended-release injection is a serotonin-3 (5-HT3) receptor antagonist that is approved by the U.S. Food and Drug Administration (FDA) and is indicated in combination with other antiemetics in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens.

Bank Name Heron Therapeutics, Inc.
Stock Exchange NASDAQ
Symbol HRTX
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region America
Chairman
CEO Dr. Barry D. Quart
Employees 145
Website www.herontx.com
Registered Year 1983

UpdateContent
UpdateContent
UpdateContent